Amylyx Pharmaceuticals, Inc. (AMLX) Tops Q2 EPS by 12c

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q2 EPS of $0.31, $0.12 better than the analyst estimate of $0.19. Revenue for the quarter came in at $98.22 million versus the consensus estimate of $92.14 million.

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
• Green Dot and CommerceOne shareholders approve acquisition deal